Idarucizumab for Dabigatran Reversal — Full Cohort AnalysisCharles V. Pollack, Jeffrey I. Weitz, Pieter W. Kamphuisen et al.|New England Journal of Medicine|2017Cited by 1.1k
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatranPaul A. Reilly, Charles V. Pollack, Richard A. Bernstein et al.|Thrombosis and Haemostasis|2015Cited by 154
INITIAL RESULTS OF THE RE-VERSE AD TRIAL: IDARUCIZUMAB REVERSES THE ANTICOAGULANT EFFECTS OF DABIGATRAN IN PATIENTS IN AN EMERGENCY SETTING OF MAJOR BLEEDING, URGENT SURGERY OR INTERVENTIONSCharles V. Pollack, CW Kam, John W. Eikelboom et al.|Emergency Medicine Journal|2015Cited by 7
Abstract 16418: Reinitiation of Antithrombotic Therapy After Emergency Procedures or After an Uncontrolled or Life Threatening Bleeding Event. Initial Experience From the Re-verse Ad TrialCharles V. Pollack, Jeffrey I. Weitz, Paul Reilly et al.|Circulation|2015Cited by 5
IDARUCIZUMAB FOR REVERSAL OF THE ANTICOAGULANT EFFECTS OF DABIGATRAN IN PATIENTS IN AN EMERGENCY SETTING OF MAJOR BLEEDING, URGENT SURGERY, OR INTERVENTIONSCharles V. Pollack, Jeffrey I. Weitz, Paul Reilly et al.|Journal of the American College of Cardiology|2016Cited by 2